Lazcluze

Lazertinib mesilate monohydrate, the active ingredient in Lazcluze, is a EGFR tyrosine kinase inhibitor presented as an oral dosage form for oral use. It targets EGFR mutation‑positive non‑small cell lung cancer in adult patients.

GNH USA supplies Lazcluze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lazcluze is an EGFR tyrosine kinase inhibitor used in the management of EGFR‑driven lung cancer. - EGFR mutation‑positive NSCLC (first‑line): provides targeted tumor control in patients whose tumours harbour sensitizing EGFR mutations. - EGFR T790M‑positive NSCLC (post‑progression): overcomes resistance after prior EGFR‑TKI therapy. - Advanced EGFR‑mutated NSCLC (second‑line): offers an oral option when disease progresses on chemotherapy. - Maintenance therapy after response: helps sustain disease control in responders. - Combination with chemotherapy (investigational): explored to enhance efficacy in clinical studies.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhea: watery stools occurring in many patients. - Rash: acne‑like skin eruptions on the face and trunk. - Nausea: mild to moderate feeling of stomach upset. - Decreased appetite: reduced desire to eat. - Fatigue: generalized tiredness. - Dry skin: itching or flaking of the epidermis.

Serious or Rare Side Effects: - Interstitial lung disease: inflammatory lung condition that can be life‑threatening. - Elevated liver enzymes: signs of hepatic injury requiring monitoring. - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive skin detachment. - Cardiac failure: reduced heart pumping ability. - Ocular toxicity: visual disturbances or eye inflammation.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Hepatic impairment: consider dose adjustment or increased monitoring of liver function tests. - Renal impairment: assess kidney function and adjust therapy if needed. - Cardiac history: evaluate baseline ECG and monitor for QT prolongation. - Known hypersensitivity: avoid in patients with documented allergy to lazertinib or similar compounds. - Pregnancy and lactation: risk unknown; avoid use unless benefits clearly outweigh potential risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lazcluze may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure. - Concurrent EGFR TKIs: additive toxicity and overlapping adverse effects. - Antacids containing aluminum or magnesium: can impair oral absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may increase plasma concentrations. - Warfarin: monitor INR for potential anticoagulation changes. - Statins metabolized by CYP3A4 (e.g., simvastatin): watch for myopathy or rhabdomyolysis.